
Human EVA-1/MPZL2 Protein





Description	
Source	Recombinant Human EVA-1/MPZL2 Protein is expressed from HEK293 with hFc tag at the C-Terminus.
	It contains Val27-Leu154.
Accession	O60487
Molecular Weight	The protein has a predicted MW of 41.39 kDa. Due to glycosylation, the protein migrates to 50-60 kDa based on Tris-Bis PAGE result.
Endotoxin	Less than 1EU per μg by the LAL method.
Purity	> 95% as determined by Tris-Bis PAGE
	> 95% as determined by HPLC

Formulation and Storage


Formulation	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage	-20 to -80°C for 12 months as supplied from date of receipt20 to -80°C for 3-6 months in unopened state after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Background

MPZL2 encodes myelin protein zero-like 2, an adhesion molecule that mediates epithelial cell-cell interactions in several (developing) tissues. Deleterious variants of Mplz2/MPZL2 affect adhesion of the inner-ear epithelium and result in loss of structural integrity of the organ of Corti and progressive degeneration of hair cells, supporting cells, and spiral ganglion neurons.

Assay Data

Tris-Bis PAGE




Human EVA-1 on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC

Cat. No. EVA-HM201



Assay Data



The purity of Human EVA-1 is greater than 95% as determined by SEC-HPLC.